In the last several months, three novel drugs that we have been following on this blog failed in late stage clinical trials. The drugs have diverse mechanisms of action:

In the last several months, three novel drugs that we have been following on this blog failed in late stage clinical trials. The drugs have diverse mechanisms of action:
Bavituximab is a monoclonal antibody that binds to phosphatidyl serine (PS), a molecule this is expressed in the inner side of the cell membrane. The drug is being developed by Peregrine Pharmaceuticals for the treatment of non-small cell lung cancer and is in a late stage trial called SUNRISE – A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer. Continue reading